Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Tetracaine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A known ✓ | P35498 | 5/20 | 0.79 |
| ▸ | SCN2A known ✓ | Q99250 | 5/20 | 0.79 |
| ▸ | SCN3A known ✓ | Q9NY46 | 5/20 | 0.79 |
| ▸ | SCN5A known ✓ | Q14524 | 2/20 | 0.79 |
| ▸ | SCN7A known ✓ | Q01118 | 1/20 | 0.79 |
| ▸ | SCN9A known ✓ | Q15858 | 1/20 | 0.79 |
| ▸ | SCN8A known ✓ | Q9UQD0 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 5/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.79 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.79 |
| ▸ | MAOA | P21397 | 3/20 | 0.79 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.79 |
| ▸ | DRD3 | P35462 | 2/20 | 0.79 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.79 |
| ▸ | CNR1 | P21554 | 1/20 | 0.79 |
| ▸ | DRD4 | P21917 | 1/20 | 0.79 |
| ▸ | ACHE | P22303 | 1/20 | 0.79 |
| ▸ | HRH2 | P25021 | 1/20 | 0.79 |
| ▸ | HTR2A | P28223 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetracaine SCHEMBL3309470 | 0.91 | LMNA (0.82) | LMNACYP1A2SCN1ASCN2ASCN3A | |
| Butacaine SCHEMBL2161574 | 0.91 | LMNA (0.77) | LMNACYP1A2SCN1ASCN2ASCN3A | |
| P-Butylaminobenzoyldiethylaminoethyl SCHEMBL503019 | 0.90 | SCN1A (0.79) | LMNACYP1A2SCN1ASCN2ASCN3A | |
| P-Butylaminobenzoyldiethylaminoethyl SCHEMBL503018 | 0.89 | LMNA (0.79) | LMNACYP1A2SCN1ASCN2ASCN3A | |
| Tetracaine SCHEMBL34714 | 0.89 | LMNA (1.00) | LMNACYP1A2SCN1ASCN2ASCN3A | |
| Propoxycaine SCHEMBL2160247 | 0.88 | CYP1A2 (0.66) | LMNACYP1A2SCN1ASCN2ASCN3A | |
| Tetracaine SCHEMBL28641231 | 0.88 | LMNA (0.97) | LMNACYP1A2SCN1ASCN2ASCN3A | |
| Tetracaine SCHEMBL24370 | 0.88 | LMNA (1.00) | LMNACYP1A2SCN1ASCN2ASCN3A | |
| Tetracaine SCHEMBL3176478 | 0.88 | LMNA (0.97) | LMNACYP1A2SCN1ASCN2ASCN3A | |
| Tetracaine SCHEMBL27896875 | 0.88 | LMNA (0.97) | LMNACYP1A2SCN1ASCN2ASCN3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100316678-A1 | COMBINATION METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROPATHIC PAIN | CNSBIO PTY LTD. (AU) | 2010-12-16 | — | — | US | claimed |
| EP-2175886-A1 | COMBINATION METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROPATHIC PAIN | CNSBio Pty Ltd (AU) | 2010-04-21 | — | — | EP | claimed |
| WO-2009000038-A1 | COMBINATION METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROPATHIC PAIN | CNSBIO PTY LTD (AU) | 2008-12-31 | — | — | WO | claimed |
| US-20070184020-A1 | COMBINATION OF RADIO WAVES WITH PHARMACOLOGICALLY ACTIVE SUBSTANCES | Kalbe, Jochen (DE) | 2007-08-09 | — | — | US | claimed |
| EP-4245294-A1 | CATHETER SLIDE WITH ENHANCED STABILITY | Pharmazeutische Fabrik Montavit Ges.m.b.H. (AT) | 2023-09-20 | — | — | EP | disclosed |
| EP-4215209-A1 | A METHOD OF TREATMENT | The University of Melbourne (AU) | 2023-07-26 | — | — | EP | disclosed |
| EP-3041506-B1 | A METHOD OF TREATMENT | UNIV MELBOURNE (AU) | 2022-12-14 | — | — | EP | disclosed |
| US-9988445-B2 | Method of treatment of pain by administration of a CCL17 specific antibody | THE UNIVERSITY OF MELBOURNE (AU) | 2018-06-05 | — | — | US | disclosed |
| US-20160200808-A1 | METHOD OF TREATMENT | THE UNIVERSITY OF MELBOURNE (AU) | 2016-07-14 | — | — | US | disclosed |
| EP-3041506-A1 | A METHOD OF TREATMENT | The University of Melbourne (AU) | 2016-07-13 | — | — | EP | disclosed |
| WO-2015027296-A1 | A METHOD OF TREATMENT | THE UNIVERSITY OF MELBOURNE (AU) | 2015-03-05 | — | — | WO | disclosed |
| US-20110224147-A1 | METHODS AND COMPOSITIONS | Relevare Aust. Pyt. Ltd. (AU) | 2011-09-15 | — | — | US | disclosed |
| WO-2010012043-A1 | METHODS AND COMPOSITIONS | CNSBIO PTY LTD (AU) | 2010-02-04 | — | — | WO | disclosed |
| US-20090285862-A1 | METHODS AND COMPOSITION FOR TREATMENT OF INFLAMMATORY PAIN | CNSBIO PTY LTD. (AU) | 2009-11-19 | — | — | US | disclosed |
| WO-2009135258-A1 | METHODS AND COMPOSITIONS FOR THE MANAGEMENT OF PAIN USING OMEGA-CONOTOXINS | CNSBIO PTY LTD (AU) | 2009-11-12 | — | — | WO | disclosed |
| CN-101484165-A | Methods and composition for treatment of inflammatory pain | CNSBIO PTY LTD (AU) | 2009-07-15 | — | — | CN | disclosed |
| EP-2021005-A1 | METHODS AND COMPOSITION FOR TREATMENT OF INFLAMMATORY PAIN | CNSBIO PTY LTD (AU) | 2009-02-11 | — | — | EP | disclosed |
| WO-2009000038-A1 | COMBINATION METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROPATHIC PAIN | CNSBIO PTY LTD (AU) | 2008-12-31 | — | — | WO | disclosed |
| WO-2007128056-A1 | METHODS AND COMPOSITION FOR TREATMENT OF INFLAMMATORY PAIN | CNSBIO PTY LTD (AU) | 2007-11-15 | — | — | WO | disclosed |
| US-20070184020-A1 | COMBINATION OF RADIO WAVES WITH PHARMACOLOGICALLY ACTIVE SUBSTANCES | Kalbe, Jochen (DE) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224147-A1 | METHODS AND COMPOSITIONS | OPRK1, OPRL1, OPRM1 | SCN1A 699/4885SCN2A 557/4885SCN3A 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.